Omnicell Inc (OMCL) is a publicly traded Healthcare sector company. As of May 21, 2026, OMCL trades at $44.42 with a market cap of $1.97B and a P/E ratio of 101.06. OMCL moved +2.07% today. Year to date, OMCL is -4.71%; over the trailing twelve months it is +55.39%. Its 52-week range spans $22.66 to $55.75. Analyst consensus is strong buy with an average price target of $59.80. Rallies surfaces OMCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Omnicell Sees 15% Q1 Revenue Growth, Swings to Profit and Raises 2026 Outlook: Omnicell posted 15% year-over-year revenue growth to $310 million in Q1, swinging to $11 million GAAP net income and $25 million non-GAAP net income while non-GAAP EBITDA nearly doubled to $45 million. The company raised 2026 full-year guidance to $153–168 million EBITDA and $1.80–2.00 EPS.
| Metric | Value |
|---|---|
| Price | $44.42 |
| Market Cap | $1.97B |
| P/E Ratio | 101.06 |
| EPS | $0.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $55.75 |
| 52-Week Low | $22.66 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.23B |
| Net Income | $20.43M |
| Gross Margin | 43.50% |
6 analysts cover OMCL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $59.80.